A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Recurrent Dysarthria and Ataxia in a Young Girl
JAMA Neurol 75:125-126, Romba, M.,et al, 2018
Rebound Syndrome in Patients with Multiple Sclerosis after Cessation of Fingolimod Treatment
JAMA Neurol 73:790-794, Hatcher, S.E.,et al, 2016
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
Critical Vasospasm During Fingolimod (FTY720) Treatment in a Patient With Multiple Sclerosis
Neurol 74:2022-2024, Schwarz,A., et al, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Clinicopath Conf., Endheim-Chester Disease
NEJM 359:736-747, Case 25-2008, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004
A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018
Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018
CNS Posttransplant Lymphoproliferative Disorder
Neurol 89:e32-e37, Kesari, N.K.,et al, 2017
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised
Neurol 79:2125-2132, Tan, L.,et al, 2012
Encephalitis Associated with Glutamic Acid Decarboxylase Autoantibodies in a Child A Treatable Condition?
Arch Neurol 68:1065-1068, Korff, C.M.,et al, 2011
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women with New-Onset Epilepsy
Arch Neurol 66:458-464, Niehusmann,P.,et al, 2009